Fosnetupitant
A prodrug of netupitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, particularly delayed nausea. After intravenous administration, it is rapidly converted to netupitant which blocks substance P from triggering nausea signals in the brain. It is often combined with a 5-HT3 antagonist for broader antiemetic coverage.
Berat Molekul
688,6000 g/mol
LogP
5,00
TPSA
106,00 Ų
Lipinski RO5
Gagal
Mekanisme Kerja
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Struktur 2D
Cite this structure
Embed this structure
SMILES
Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
InChI
InChI=1S/C31H35F6N4O5P/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45)
Molecular Formula
C31H35F6N4O5P
HBD / HBA
1 / 13
Ikatan yang Dapat Dirotasi
8
Atom Berat
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A prodrug of netupitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, particularly delayed nausea. After intravenous administration, it is rapidly converted to netupitant which blocks substance P from triggering nausea signals in the brain. It is often combined with a 5-HT3 antagonist for broader antiemetic coverage.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Fosnetupitant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989917. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71544786. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fosnetupitant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fosnetupitant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fosnetupitant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fosnetupitant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fosnetupitant"></drugfyi-drug>